Search Results - "IYEVLEVA, Aglaya G"

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation by Gorodnova, Tatiana V, Sokolenko, Anna P, Ivantsov, Alexandr O, Iyevleva, Aglaya G, Suspitsin, Evgeny N, Aleksakhina, Svetlana N, Yanus, Grigory A, Togo, Alexandr V, Maximov, Sergey Ya, Imyanitov, Evgeny N

“…Highlights • Ovarian carcinomas arising in BRCA1/2 germ-line mutation carriers show high sensitivity to platinum-based neoadjuvant therapy. • Chemonaive…”
Get full text

Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability by Iyevleva, Aglaya G., Aleksakhina, Svetlana N., Sokolenko, Anna P., Baskina, Sofia V., Venina, Aigul R., Anisimova, Elena I., Bizin, Ilya V., Ivantsov, Alexandr O., Belysheva, Yana V., Chernyakova, Alexandra P., Togo, Alexandr V., Imyanitov, Evgeny N.

“…Purpose Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to…”
Get full text

Molecular profiles of BRCA1‐associated ovarian cancer treated by platinum‐based therapy: Analysis of primary, residual and relapsed tumors by Sokolenko, Anna P., Bizin, Ilya V., Preobrazhenskaya, Elena V., Gorodnova, Tatiana V., Ivantsov, Alexander O., Iyevleva, Aglaya G., Savonevich, Elena L., Kotiv, Khristina B., Kuligina, Ekaterina Sh, Imyanitov, Evgeny N.

“…Our study aimed to analyze the evolution of molecular portraits of BRCA1‐driven ovarian cancer (OC) during treatment. BRCA1 loss‐of‐heterozygosity status (LOH)…”
Get full text

Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples by Romanko, Aleksandr A., Mulkidjan, Rimma S., Tiurin, Vladislav I., Saitova, Evgeniya S., Preobrazhenskaya, Elena V., Krivosheyeva, Elena A., Mitiushkina, Natalia V., Shestakova, Anna D., Belogubova, Evgeniya V., Ivantsov, Alexandr O., Iyevleva, Aglaya G., Imyanitov, Evgeny N.

“…The majority of NTRK1, NTRK2, and NTRK3 rearrangements result in increased expression of the kinase portion of the involved gene due to its fusion to an…”
Get full text

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1 -Driven Breast Cancer Patients by Sokolenko, Anna P, Moiseyenko, Fedor V, Iyevleva, Aglaya G, Ivantsov, Alexandr O, Dolmatov, Georgiy D, Shelekhova, Ksenia V, Gulo, Elizaveta V, Topal, Anastasya X, Artemieva, Elizaveta V, Abduloeva, Nuriniso H, Rysev, Nikita A, Barsova, Daria A, Levchenko, Natalia V, Volkov, Nikita M, Egorenkov, Vitaliy V, Moiseyenko, Vladimir M, Imyanitov, Evgeny N

“…Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer…”
Get full text

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives by Imyanitov, Evgeny N., Iyevleva, Aglaya G., Levchenko, Evgeny V.

“…[Display omitted] •There are approved targeted drugs for NSCLCs carrying EGFR, BRAF and MET mutations.•NSCLC testing guidelines include the analysis of ALK,…”
Get full text

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment by Protsenko, Svetlana A., Semionova, Anna I., Komarov, Yuri I., Aleksakhina, Svetlana N., Ivantsov, Alexandr O., Iyevleva, Aglaya G., Imyanitov, Evgeny N.

“…Summary We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin…”
Get full text

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study by Orlov, Sergey V., Iyevleva, Aglaya G., Filippova, Elena A., Lozhkina, Alexandra M., Odintsova, Svetlana V., Sokolova, Tatiana N., Mitiushkina, Natalia V., Tiurin, Vladislav I., Preobrazhenskaya, Elena V., Romanko, Alexandr A., Martianov, Alexandr S., Ivantsov, Alexandr O., Aleksakhina, Svetlana N., Togo, Alexandr V., Imyanitov, Evgeny N.

“…•In patients with ALK-rearranged NSCLC who received lorlatinib within the compassionate use program, the objective tumor response (OR) and disease control (DC)…”
Get full text

High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas by Iyevleva, Aglaya G., Kuligina, Ekatherina Sh, Mitiushkina, Nathalia V., Togo, Alexandr V., Miki, Yoshio, Imyanitov, Evgeny N.

“…We analyzed the expression of several microRNAs (miRs) implicated in breast cancer (BC) pathogenesis (miR-21, miR-10b, miR17-5p, mir-31, miR-155, miR-200c,…”
Get full text

Detection of EGFR mutations and EML4‐ALK rearrangements in lung adenocarcinomas using archived cytological slides by Mitiushkina, Natalia V., Iyevleva, Aglaya G., Poltoratskiy, Artiom N., Ivantsov, Alexandr O., Togo, Alexandr V., Polyakov, Igor S., Orlov, Sergey V., Matsko, Dmitry E., Novik, Viktor I., Imyanitov, Evgeny N.

“…BACKGROUND Although the molecular analysis of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in archived lung cancer tissues is…”
Get full text

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs by Imyanitov, Evgeny N., Iyevleva, Aglaya G.

“…Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended…”
Get full text

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation р.T632I by Orlova, Kristina V., Yanus, Grigory A., Aleksakhina, Svetlana N., Venina, Aigul R., Iyevleva, Aglaya G., Demidov, Lev V., Imyanitov, Evgeny N.

“…Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of…”
Get full text

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia by Sokolenko, Anna P, Rozanov, Maxim E, Mitiushkina, Natalia V, Sherina, Natalia Yu, Iyevleva, Aglaya G, Chekmariova, Elena V, Buslov, Konstantin G, Shilov, Evgeny S, Togo, Alexandr V, Bit-Sava, Elena M, Voskresenskiy, Dmitry A, Chagunava, Oleg L, Devilee, Peter, Cornelisse, Cees, Semiglazov, Vladimir F, Imyanitov, Evgeny N

“…Previous studies indicate that founder mutations may play a noticeable role in breast cancer (BC) predisposition in Russia. Here we performed a systematic…”
Get full text

Cytotoxic and targeted therapy for hereditary cancers by Iyevleva, Aglaya G, Imyanitov, Evgeny N

“…There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via…”
Get full text

Novel ALK fusion partners in lung cancer by Iyevleva, Aglaya G, Raskin, Grigory A, Tiurin, Vladislav I, Sokolenko, Anna P, Mitiushkina, Natalia V, Aleksakhina, Svetlana N, Garifullina, Aigul R, Strelkova, Tatiana N, Merkulov, Valery O, Ivantsov, Alexandr O, Kuligina, Ekatherina Sh, Pozharisski, Kazimir M, Togo, Alexandr V, Imyanitov, Evgeny N

“…Highlights • Combination of two distinct PCR assays is a highly reliable approach for detection of both known and new ALK translocations. • Two novel ALK…”
Get full text

EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: A case report by Iyevleva, Aglaya G., M.D, Novik, Alexey V., M.D., Ph.D, Moiseyenko, Vladimir M., M.D., Ph.D, Imyanitov, Evgeny N., M.D., Ph.D

“…Abstract Mutations of the epidermal growth factor receptor (EGFR) gene are known to be associated with the pronounced tumor response to EGFR tyrosine kinase…”
Get full text

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas by Martianov, Aleksandr S, Mitiushkina, Natalia V, Ershova, Anastasia N, Martynenko, Darya E, Bubnov, Mikhail G, Amankwah, Priscilla, Yanus, Grigory A, Aleksakhina, Svetlana N, Tiurin, Vladislav I, Venina, Aigul R, Anuskina, Aleksandra A, Gorgul, Yuliy A, Shestakova, Anna D, Maidin, Mikhail A, Belyaev, Alexey M, Baboshkina, Liliya S, Iyevleva, Aglaya G, Imyanitov, Evgeny N

“…This study aimed to analyze clinical and regional factors influencing the distribution of actionable genetic alterations in a large consecutive series of…”
Get full text

Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings by Kuligina, Ekaterina S., Iyevleva, Aglaya G., Imyanitov, Evgeny N.

Get full text

Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors by Preobrazhenskaya, Elena V., Iyevleva, Aglaya G., Suleymanova, Amina M., Tiurin, Vladislav I., Mitiushkina, Natalia V., Bizin, Ilya V., Ivanstov, Alexandr O., Gorustovich, Olga A., Shelekhova, Kseniya V., Kachanov, Denis Y., Varfolomeeva, Svetlana R., Roschin, Vitaliy Y., Kazakova, Anna N., Litvinov, Dmitriy V., Shamanskaya, Tatiana V., Savelov, Nikita A., Suspitsin, Evgeny N., Imyanitov, Evgeny N.

“…Background Inflammatory myofibroblastic tumors (IMTs) are exceptionally rare neoplasms, which are often driven by rearranged tyrosine kinases. Methods This…”
Get full text

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas by Tiurin, Vladislav I, Preobrazhenskaya, Elena V, Mitiushkina, Natalia V, Romanko, Aleksandr A, Anuskina, Aleksandra A, Mulkidjan, Rimma S, Saitova, Evgeniya S, Krivosheyeva, Elena A, Kharitonova, Elena D, Shevyakov, Mikhail P, Tryakin, Ilya A, Aleksakhina, Svetlana N, Venina, Aigul R, Sokolova, Tatiana N, Martianov, Aleksandr S, Shestakova, Anna D, Ivantsov, Alexandr O, Iyevleva, Aglaya G, Imyanitov, Evgeny N

“…-kinase-activating gene rearrangements occur in approximately 1-2% of non-small-cell lung carcinomas (NSCLCs). Their reliable detection requires…”
Get full text